Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions
Clinical Infectious Diseases · 17.02.2024 · 78 (2) · 248-258
DOI: 10.1093/cid/ciad556 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 20.09.2023. Verfasst von Minggui Wang und 42 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections. Die Arbeit wurde bisher 115-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, VA.
Abstract (Originalsprache)
Background
Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb.
Methods
In a prospective observational cohort study, 842 hospitalized patients with a clinical CRAb culture were enrolled at 46 hospitals in five global regions between 2017 and 2019. The primary outcome was all-cause mortality at 30 days from the index culture. The strains underwent whole-genome analysis.
Results
Of 842 cases, 536 (64%) represented infection. By 30 days, 128 (24%) of the infected patients died, ranging from 1 (6%) of 18 in Australia-Singapore to 54 (25%) of 216 in the United States and 24 (49%) of 49 in South-Central America, whereas 42 (14%) of non-infected patients died. Bacteremia was associated with a higher risk of death compared with other types of infection (40 [42%] of 96 vs 88 [20%] of 440). In a multivariable logistic regression analysis, bloodstream infection and higher age-adjusted Charlson comorbidity index were independently associated with 30-day mortality. Clonal group 2 (CG2) strains predominated except in South-Central America, ranging from 216 (59%) of 369 in the United States to 282 (97%) of 291 in China. Acquired carbapenemase genes were carried by 769 (91%) of the 842 isolates. CG2 strains were significantly associated with higher levels of meropenem resistance, yet non-CG2 cases were over-represented among the deaths compared with CG2 cases.
Conclusions
CRAb infection types and clinical outcomes differed significantly across regions. Although CG2 strains remained predominant, non-CG2 strains were associated with higher mortality. Clinical Trials Registration. NCT03646227.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People's Republic of China,Shanghai, China.
- The Biostatistics Center, George Washington University, Rockville, Maryland, USA.
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
- Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
- Center for Infectious Diseases and Microbial Genomics, UTHealth, McGovern School of Medicine at Houston, Houston, Texas, USA.
ORCID-Profile: Minggui Wang, Blake Hanson, Yunsong Yu, Ezequiel Cordova, Keith S Kaye, Scott R Evans, Robin Patel, David van Duin
Förderung
- NIAID NIH HHS
- NIH HHS
- VA
- NIAID
- NIH
- National Natural Science Foundation of China
- Department of Veterans Affairs
Zitieren
APA
Wang, M., Ge, L., Chen, L., Komarow, L., Hanson, B., Reyes, J., Cober, E., Alenazi, T., Zong, Z., Xie, Q., Liu, Z., Li, L., Yu, Y., Gao, H., Kanj, S. S., Figueroa, J., Herc, E., Cordova, E., Weston, G., …, & Multi-Drug Resistant Organism Network Investigators (2024). Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clinical Infectious Diseases, 78(2), 248-258. https://doi.org/10.1093/cid/ciad556
Vancouver
Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, et al. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clinical Infectious Diseases. 2024;78(2):248-258. doi:10.1093/cid/ciad556
BibTeX
@article{Wang2024,
author = {Wang, Minggui and Ge, Lizhao and Chen, Liang and Komarow, Lauren and Hanson, Blake and Reyes, Jinnethe and Cober, Eric and Alenazi, Thamer and Zong, Zhiyong and Xie, Qing and Liu, Zhengyin and Li, Lanjuan and Yu, Yunsong and Gao, Hainv and Kanj, Souha S and Figueroa, Jairo and Herc, Erica and Cordova, Ezequiel and Weston, Gregory and Ananth Tambyah, Paul and Garcia-Diaz, Julia and Kaye, Keith S and Dhar, Sorabh and Munita, Jose M and Salata, Robert A and Vilchez, Samuel and Stryjewski, Martin E and Villegas Botero, Maria Virginia and Iovleva, Alina and Evans, Scott R and Baum, Keri and Hill, Carol and Kreiswirth, Barry N and Patel, Robin and Paterson, David L and Arias, Cesar A and Bonomo, Robert A and Chambers, Henry F and Fowler, Vance G and Satlin, Michael J and van Duin, David and Doi, Yohei and Multi-Drug Resistant Organism Network Investigators, Multi-Drug Resistant Organism Network Investigators},
title = {Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {78},
number = {2},
pages = {248--258},
doi = {10.1093/cid/ciad556}
}
EUVIMED